Personalized mRNA Cancer Vaccine Significantly Reduces Melanoma Recurrence in Trial

Phase 3 clinical trial results presented at the 2026 ESMO Congress indicate that a personalized mRNA cancer vaccine, when combined with pembrolizumab, significantly reduced the risk of melanoma recurrence or spread by 42%. The combination therapy also lowered the risk of distant metastasis or death by 38% compared to pembrolizumab alone. At 24 months, 17.8% of vaccine group patients experienced recurrence or death, versus 30% in the control group, marking a substantial improvement in outcomes for melanoma patients.